Back to Archived Journals » Biosimilars

Biosimilars ceased publishing in October 2016. All new submissions can be made to Biologics: Targets and Therapy. All articles that have been published in Biosimilars will continue to be available on the Dove Press site, and will be securely archived with CLOCKSS.

Journal Articles:

- 31 records -

Physicochemical and biological comparison of the first Brazilian biosimilar filgrastim with its reference product

Mantovani M, Caruso CS, Facchini FDA, Pascon R, Cagnacci PRV, de Magalhães VD

Biosimilars 2016, 6:45-60

Published Date: 30 August 2016

Adalimumab: a review of the reference product and biosimilars

Azevedo VF, Troiano LDC, Galli NB, Kleinfelder A, Catolino NM, Martins PCU

Biosimilars 2016, 6:29-44

Published Date: 26 July 2016

Tools for the analysis and characterization of therapeutic protein species

Fuh MM, Steffen P, Schlüter H

Biosimilars 2016, 6:17-24

Published Date: 5 May 2016

Considerations in biosimilar insulin device development

Fry AR, Krentz AJ, Hompesch M

Biosimilars 2016, 6:9-15

Published Date: 16 February 2016

Development, safety, and efficacy of biosimilar adalimumab: the data so far

Gabbani T, Deiana S, Bagnoli S, Annese V

Biosimilars 2016, 6:1-7

Published Date: 29 January 2016

Label-free interaction analysis as a tool to demonstrate biosimilarity of therapeutic monoclonal antibodies

Sinha-Datta U, Khan S, Wadgaonkar D

Biosimilars 2015, 5:83-91

Published Date: 16 September 2015

Low immunogenicity but reduced bioavailability of an interferon beta-1a biosimilar compared with its biological parent: results of MATRIX, a cross-sectional, multicenter phase 4 study

Cuevas C, Deisenhammer F, You X, Scolnik M, Buffels R, Sperling B, Flores-Ramírez F, Macías-Islas M, Sauri-Suárez S

Biosimilars 2015, 5:75-81

Published Date: 15 September 2015

Clinical efficacy and safety of biosimilar epoetin: focus on epoetin zeta

Mikhail A, Brown C

Biosimilars 2015, 5:65-73

Published Date: 9 September 2015

Clinical trials in the development of biosimilars: future considerations

Huneycutt BJ, Gillespie E, Woollett GR

Biosimilars 2015, 5:49-63

Published Date: 9 July 2015

Challenging issues in assessing analytical similarity in biosimilar studies

Chow SC

Biosimilars 2015, 5:33-39

Published Date: 22 May 2015

Global regulatory landscape of biosimilars: emerging and established market perspectives

Krishnan A, Mody R, Malhotra H

Biosimilars 2015, 5:19-32

Published Date: 17 February 2015

Physicochemical and functional characterization of a biosimilar adalimumab ZRC-3197

Bandyopadhyay S, Mahajan M, Mehta T, Singh AK, Parikh A, Gupta AK, Kalita P, Patel M, Mendiratta SK

Biosimilars 2015, 5:1-18

Published Date: 31 December 2014

Production and analysis of a biosimilar erythropoietin in Egypt

Ebied WM, Ahmed HM, Elbarbry FA

Biosimilars 2014, 4:11-22

Published Date: 10 May 2014

Clinical efficacy and safety of Zarzio® (EP2006), a biosimilar recombinant human granulocyte colony-stimulating factor

Tharmarajah S, Mohammed A, Bagalagel A, MacDonald K, Abraham I

Biosimilars 2014, 4:1-9

Published Date: 12 March 2014

Clinical efficacy and safety of Tevagrastim® (XM02), a biosimilar recombinant human granulocyte colony-stimulating factor

Bagalagel A, Mohammed A, MacDonald K, Abraham I

Biosimilars 2013, 3:55-62

Published Date: 27 August 2013

Clinical efficacy and safety of XM01, a biosimilar recombinant human erythropoietin, in the management of anemia

Mohammed A, Bagalagel A, MacDonald K, Abraham I

Biosimilars 2013, 3:45-53

Published Date: 27 August 2013

Clinical efficacy and safety of SB309, a biosimilar recombinant human erythropoietin, in the management of anemia

Bagalagel A, Mohammed A, MacDonald K, Abraham I

Biosimilars 2013, 3:35-43

Published Date: 21 August 2013

Current and future biosimilars: potential practical applications in rheumatology

Noaiseh G, Moreland L

Biosimilars 2013, 3:27-33

Published Date: 1 August 2013

Rituximab and biosimilars – equivalence and reciprocity

Qureshi ZP, Magwood JS, Singh S, Bennett CL

Biosimilars 2013, 3:19-25

Published Date: 14 June 2013

Similar biotherapeutic products in Latin America. Regulation and opportunities for patients with autoimmune diseases

Desanvicente-Celis Z, Caro-Moreno J, Enciso-Zuluaga M, Anaya JM

Biosimilars 2013, 3:1-17

Published Date: 4 January 2013

A European perspective on the market accessibility of biosimilars

Declerck PJ, Simoens S

Biosimilars 2012, 2:33-40

Published Date: 16 November 2012

Scientific factors for assessing biosimilarity and drug interchangeability of follow-on biologics

Chow SC, Endrenyi L, Lachenbruch PA, Yang LY, Chi E

Biosimilars 2011, 1:13-26

Published Date: 16 June 2011

Biosimilars: an overview

Bhupinder Singh Sekhon, Vikrant Saluja

Biosimilars 2011, 1:1-11

Published Date: 15 March 2011